US EditionBlocking LSD1, GSK3 could be treatment strategy for AML
Summary by rarecancernews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Blocking LSD1, GSK3 could be treatment strategy for AML
Simultaneously blocking the activity of two proteins, LSD1 and GSK3, may be an effective strategy to treat acute myeloid leukemia (AML), an aggressive type of blood cancer, according to a study done in mouse and cell models. “Our findings provide compelling evidence to support the testing of this combination therapy in AML patients, especially since both of the inhibitors involved are not only available but have been developed for human use and …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
